Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BDC-4182

Antibody-drug conjugate · Immune activation, directed at claudin 18.2 (CLDN18) · developed by Bolt Biotherapeutics

Phase 1/2 Most advanced trial
BOLT Developer
1 Registered trials

What is BDC-4182?

BDC-4182 is an immune stimulating antibody conjugate made of an anti-claudin 18.2 monoclonal antibody linked to a TLR 7/8 dual agonist. The antibody directs the conjugate to claudin 18.2 on tumor cells, where the TLR 7/8 agonist payload stimulates innate immune activity. It is being studied in metastatic gastric and gastroesophageal adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
claudin 18.2 (CLDN18)
Mechanism
Immune activation, directed at claudin 18.2 (CLDN18)
Pathways
TLR7/8 signaling
Therapy area
Oncology
Developer
Bolt Biotherapeutics, Inc. (BOLT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06921837 Phase 1/2 Gastric Cancer Adenocarcinoma Metastatic Recruiting BOLT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastric Cancer Adenocarcinoma MetastaticGastroesophageal Adenocarcinoma

Other drugs acting on CLDN18

More from Bolt Biotherapeutics

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the BOLT page.

Follow BOLT, the company behind BDC-4182

See BOLT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BOLT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.